Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + ADT + RT for High Risk Localized Prostate Cancer
NCT06528210Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Planned start Apr 2025; status: withdrawn.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06528210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06528210.